CENTESSA PHARMACEUTICALS-ADR (CNTA) Fundamental Analysis & Valuation

NASDAQ:CNTA • US1523091007

28.22 USD
+0.63 (+2.28%)
At close: Mar 11, 2026
28.22 USD
0 (0%)
After Hours: 3/11/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CNTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

CNTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. The financial health of CNTA is average, but there are quite some concerns on its profitability. CNTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. CNTA Profitability Analysis

1.1 Basic Checks

  • CNTA had negative earnings in the past year.
  • In the past year CNTA has reported a negative cash flow from operations.
  • In the past 5 years CNTA always reported negative net income.
  • CNTA had a negative operating cash flow in each of the past 5 years.
CNTA Yearly Net Income VS EBIT VS OCF VS FCFCNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • CNTA has a Return On Assets (-54.14%) which is in line with its industry peers.
  • CNTA has a Return On Equity of -80.48%. This is comparable to the rest of the industry: CNTA outperforms 50.87% of its industry peers.
Industry RankSector Rank
ROA -54.14%
ROE -80.48%
ROIC N/A
ROA(3y)-43.83%
ROA(5y)-56.62%
ROE(3y)-62.33%
ROE(5y)-121.67%
ROIC(3y)N/A
ROIC(5y)N/A
CNTA Yearly ROA, ROE, ROICCNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • CNTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTA Yearly Profit, Operating, Gross MarginsCNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CNTA Health Analysis

2.1 Basic Checks

  • CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CNTA has been increased compared to 1 year ago.
  • CNTA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CNTA has an improved debt to assets ratio.
CNTA Yearly Shares OutstandingCNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M
CNTA Yearly Total Debt VS Total AssetsCNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 12.38 indicates that CNTA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CNTA (12.38) is better than 83.81% of its industry peers.
  • A Debt/Equity ratio of 0.36 indicates that CNTA is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.36, CNTA is not doing good in the industry: 68.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 12.38
ROIC/WACCN/A
WACC9.35%
CNTA Yearly LT Debt VS Equity VS FCFCNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • CNTA has a Current Ratio of 10.57. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.
  • CNTA has a better Current ratio (10.57) than 83.24% of its industry peers.
  • A Quick Ratio of 10.57 indicates that CNTA has no problem at all paying its short term obligations.
  • CNTA's Quick ratio of 10.57 is amongst the best of the industry. CNTA outperforms 83.24% of its industry peers.
Industry RankSector Rank
Current Ratio 10.57
Quick Ratio 10.57
CNTA Yearly Current Assets VS Current LiabilitesCNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. CNTA Growth Analysis

3.1 Past

  • CNTA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.61%.
  • The Revenue has grown by 118.88% in the past year. This is a very strong growth!
EPS 1Y (TTM)-2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.81%
Revenue 1Y (TTM)118.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CNTA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.68% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.5%
EPS Next 2Y1.58%
EPS Next 3Y-0.01%
EPS Next 5Y15.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTA Yearly Revenue VS EstimatesCNTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
CNTA Yearly EPS VS EstimatesCNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CNTA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNTA. In the last year negative earnings were reported.
  • Also next year CNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTA Price Earnings VS Forward Price EarningsCNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTA Per share dataCNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.58%
EPS Next 3Y-0.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CNTA Dividend Analysis

5.1 Amount

  • No dividends for CNTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CNTA Fundamentals: All Metrics, Ratios and Statistics

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (3/11/2026, 8:00:00 PM)

After market: 28.22 0 (0%)

28.22

+0.63 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-23
Inst Owners92.47%
Inst Owner Change15.71%
Ins Owners0.61%
Ins Owner Change2.11%
Market Cap4.17B
Revenue(TTM)15.00M
Net Income(TTM)-242.70M
Analysts86.36
Price Target40.41 (43.2%)
Short Float %4.52%
Short Ratio4.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.73%
Min EPS beat(2)-7.99%
Max EPS beat(2)-3.48%
EPS beat(4)1
Avg EPS beat(4)2.12%
Min EPS beat(4)-27.41%
Max EPS beat(4)47.36%
EPS beat(8)4
Avg EPS beat(8)6.78%
EPS beat(12)7
Avg EPS beat(12)9.07%
EPS beat(16)9
Avg EPS beat(16)5.94%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.85%
EPS NQ rev (1m)0.6%
EPS NQ rev (3m)0.6%
EPS NY rev (1m)0.11%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 278.1
P/FCF N/A
P/OCF N/A
P/B 13.83
P/tB 13.83
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0.1
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.14%
ROE -80.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.83%
ROA(5y)-56.62%
ROE(3y)-62.33%
ROE(5y)-121.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.91%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.57
Quick Ratio 10.57
Altman-Z 12.38
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)300.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.81%
EPS Next Y18.5%
EPS Next 2Y1.58%
EPS Next 3Y-0.01%
EPS Next 5Y15.68%
Revenue 1Y (TTM)118.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.53%
EBIT Next 3Y-16.77%
EBIT Next 5YN/A
FCF growth 1Y0.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.11%
OCF growth 3YN/A
OCF growth 5YN/A

CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ

What is the ChartMill fundamental rating of CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CNTA.


What is the valuation status of CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?

ChartMill assigns a valuation rating of 0 / 10 to CENTESSA PHARMACEUTICALS-ADR (CNTA). This can be considered as Overvalued.


Can you provide the profitability details for CENTESSA PHARMACEUTICALS-ADR?

CENTESSA PHARMACEUTICALS-ADR (CNTA) has a profitability rating of 1 / 10.


Can you provide the financial health for CNTA stock?

The financial health rating of CENTESSA PHARMACEUTICALS-ADR (CNTA) is 6 / 10.